A Phase 2a, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema
Latest Information Update: 20 May 2024
At a glance
- Drugs Foselutoclax (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Proof of concept
- Acronyms BEHOLD
- Sponsors UNITY Biotechnology
- 25 Apr 2024 According to a UNITY Biotechnology media release, data from this study will be presented at the e Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington.
- 24 Apr 2023 Results published in the Media Release
- 24 Apr 2023 According to UNITY Biotechnology media release, UBX-1325 demonstrated favorable safety and tolerability profile (48 weeks data).